November 2022 EGRP Cancer Epidemiology News

EGRP Cancer Epidemiology News

Funding Opportunities to Address Benefits and Harms of Cannabis Use Among Cancer Patients

Over the past decade, the rapidly increasing availability of cannabis and cannabinoid products, the substantial changes in their delivery methods, and the dearth of information available on their harms and benefits during cancer treatment has created a need for research studies addressing cannabis and cannabinoid use among cancer patients.

In October 2022, The National Cancer Institute (NCI) published two new funding opportunity announcements (FOAs) to address gaps in knowledge and build an evidence base regarding cannabis and cannabinoid use during cancer treatment.

The deadline for submissions to both FOAs is February 17, 2023.

NCI’s Epidemiology and Genomics Research Program (EGRP) also held a pre-application webinar on October 26, 2022, and a recording of the event is availableExternal Web Site Policy. During the webinar, Drs. Kelly Filipski, Andrew Freedman, and Lisa Gallicchio provided an overview of the two FOAs, reviewed specific requirements for applications, and answered questions from the research community. Investigators interested in these FOAs are encouraged to contact Dr. Filipski with their ideas and questions.

NCI has supported a number of cannabis-related FOAs and other activities, including the virtual Cannabis, Cannabinoids, and Cancer Research Symposium, where participants discussed recent research findings on the use of cannabis and cannabinoids in relationship to cancer risk, prevention, and care. The symposium highlighted the state of the science regarding cannabis (including the chemical constituents of cannabis, a.k.a. cannabinoids) and identified promising areas of future study, current barriers to conducting the research, and strategies to overcome those barriers. A series of papers published in a December 2021 Journal of the National Cancer Institute monograph provide a summary of the symposium sessions, as well as a synopsis of opportunities and challenges related to conducting research in this area.

Further information about EGRP’s support of research related to cannabis and cannabinoids is available at

Funding Opportunities

  • RFA-CA-23-013, Transformative Educational Advancement and Mentoring Network (TEAM) (R25, Clinical Trial Not Allowed)
  • RFA-CA-23-018, Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories
  • PAR-22-239, Feasibility Studies to Build Collaborative Partnerships in Cancer Research
  • PAR-22-249, Comprehensive Partnerships to Advance Cancer Health Equity
  • NOT-CA-23-004, Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers

Requests for Information

Grants Policy Announcements

  • NOT-OD-23-006, Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: May 2023 Councils
  • NOT-OD-23-008, Clarification and Guidance for Applicants Preparing Applications for the FALL 2022 Due Dates During the COVID-19 Pandemic
  • NOT-OD-23-011, NIH Offers Ability to Bypass 2-Business Day Application Viewing Window as an Option for Administrative Supplements
  • NOT-OD-23-012, Reminder: FORMS-H Grant Application Forms & Instructions Must be Used for Due Dates On or After January 25, 2023 - New Grant Application Instructions Now Available

Training Opportunities

NIH/NCI News and Blog Posts

Stay Connected

Subscribe for Updates

You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.

Subscribe to the E-Newsletter

Need Help?

EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.

Email Us
(240) 276-6730